


Psychedelic APIs

Psychedelics are emerging as promising therapies in the treatment of various neurological and psychiatric conditions. Though psychedelics are controlled substances in most countries, clinical trials exploring the use of psychedelics are underway. The US FDA has granted breakthrough therapy status for the use of psilocybin in major depressive disorder and treatment-resistant depression, for which it has shown to be safe and effective. It may also have potential in the treatment of anxiety, substance use disorder, cluster headaches, as well as psychological distress associated with end-of-life.

- US FDA and EMA compliant
- Analytical standards of impurities and degradation products available
- DEA licensed facility for manufacturing, analysis, and export

CGMP Psilocybin



Nomenclature

Formal Name: 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol, 4-(dihydrogen phosphate)

CAS Number: 520-52-5

DEA Schedule: I

Drug Code: 7437

Formula

Molecular Formula: C₁₂H₁₇N₂O₄P · **Formula Weight:** 284.3

Physiochemical Data

Solubility: Soluble in water; slightly soluble in acetone, ethanol, and methanol

Appearance: White to tan powder

Availability


GMP material suitable for Phase 1 and Phase 2 trials is available.



Cayman Chemical

Toll Free (USA and CANADA):
+1 (800) 364-9897
Direct: +1 (734) 971-3335
Fax: +1 (734) 971-3420
GMP-API@caymanchem.com

CGMP Psilocin



Nomenclature

Formal Name: 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol

CAS Number: 520-53-6

DEA Schedule: I

Drug Code: 7438

Formula

Molecular Formula: $C_{12}H_{16}N_2O$ · **Formula Weight:** 204.3

Physiochemical Data

Solubility: Soluble in acetone, chloroform, ethanol, hexane, and methanol; slightly soluble in water

Appearance: White to beige powder

Availability

GMP material suitable for Phase 1 and Phase 2 trials is available.